Health insurer stocks slide after CMS proposes near-flat 2027 Medicare Advantage payment increase
Shares of major U.S. health insurers fell sharply after the Centers for Medicare & Medicaid Services proposed a 0.09% average increase to Medicare Advantage payment rates for 2027—far below what analysts expected. The proposal revived concerns about margins in a program covering tens of millions of Americans and intensified scrutiny of how insurers manage costs, coding practices, and benefits.
U.S. health insurer stocks tumbled on Tuesday, January 27, 2026, after the Centers for Medicare & Medicaid Services (CMS) proposed a smaller-than-expected update to Medicare Advantage payment rates for 2027. The agency’s advance notice indicated an average increase of about 0.09%, a figure that surprised investors who had expected a meaningfully higher boost.
The market reaction was swift because Medicare Advantage is central to revenue and profit for several major insurers, and even small changes in government rates can ripple through bids, benefits, and plan participation. With medical costs still elevated, investors worry that near-flat payments could force insurers to cut benefits, raise out-of-pocket costs, narrow provider networks, or pull back from some counties.
The proposed update also lands amid heightened political attention on healthcare pricing and the structure of private plans that serve seniors and people with disabilities. CMS has signaled interest in modernizing how risk adjustment and diagnostic coding influence payments—an area that has drawn criticism over the years from watchdogs who argue the system can encourage aggressive documentation practices.
UnitedHealth, Humana, CVS’s Aetna business, Elevance, and others are among the firms most exposed to Medicare Advantage trends. Analysts said the combination of tighter rates and rising utilization could compress margins in 2027 unless companies find new efficiencies or redesign plans.
Importantly, the CMS figure is still a proposal. The agency typically collects feedback from insurers, providers, advocates, and lawmakers before issuing a final rate announcement later in the year. Companies will use that final number to inform benefit designs and bids for the 2027 plan year.
For now, the proposed 0.09% increase has become a key data point for Wall Street: it suggests a tougher reimbursement climate ahead, increasing pressure on insurers to justify pricing, improve care management, and demonstrate that private-plan participation delivers value to beneficiaries and taxpayers.